

TDMs No. 88148 - 07

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)**

Date Report Reqsted: 02/27/2008

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Reqsted: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

F\_1\_ M3

C Number: C88148C

Lock Date: 08/31/2005

Cage Range: ALL

Date Range: ALL

Reasons For Removal: 25022 ACCK                      25021 TSAC                      25020 NATD  
25019 MSAC                      25018 DACC

Removal Date Range: ALL

Treatment Groups: Include ALL

TDMSE Version: 1.9.1

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed			1	
Dosing Accident	1		1	
Moribund Sacrifice	10	11	16	19
Natural Death	4	8	26	31
Survivors				
Terminal Sacrifice	35	31	5	
Animals Examined Microscopically	50	50	49	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(49)	(50)
Gallbladder	(49)	(50)	(49)	(50)
Intestine Large, Cecum	(50)	(50)	(49)	(50)
Intestine Large, Rectum	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Urethra				1 (2%)
Intestine Small, Duodenum	(50)	(50)	(49)	(50)
Adenoma		1 (2%)		
Intestine Small, Ileum	(50)	(50)	(49)	(50)
Carcinoma			1 (2%)	
Intestine Small, Jejunum	(50)	(50)	(49)	(50)
Carcinoma	2 (4%)		1 (2%)	
Liver	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma		2 (4%)		
Hemangiosarcoma, Multiple	1 (2%)			
Hepatoblastoma	2 (4%)	1 (2%)		
Hepatocellular Adenoma	12 (24%)	14 (28%)	10 (20%)	2 (4%)
Hepatocellular Adenoma, Multiple	10 (20%)	13 (26%)	7 (14%)	
Hepatocellular Carcinoma	14 (28%)	10 (20%)	7 (14%)	
Hepatocellular Carcinoma, Multiple	3 (6%)		1 (2%)	
Hepatocholangiocarcinoma	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Mesentery	(5)	(5)	(4)	(2)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (25%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (20%)			
Carcinoma, Metastatic, Uncertain Primary Site				1 (50%)
Carcinoma, Metastatic, Urethra			1 (25%)	
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Salivary Glands	(50)	(50)	(49)	(50)
Stomach, Forestomach	(50)	(50)	(49)	(50)
Squamous Cell Carcinoma		1 (2%)	1 (2%)	3 (6%)
Squamous Cell Papilloma	1 (2%)			1 (2%)
Stomach, Glandular	(50)	(50)	(49)	(50)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach		1 (2%)	1 (2%)	1 (2%)
Tongue	(0)	(1)	(0)	(0)
Tooth	(8)	(3)	(0)	(0)
Odontoma	1 (13%)			
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(50)	(50)	(49)	(50)
Aorta, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Heart	(50)	(50)	(49)	(50)
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Hemangiosarcoma		1 (2%)		
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Hemangiosarcoma, Metastatic, Kidney	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Subcapsular, Adenoma	3 (6%)	1 (2%)		
Islets, Pancreatic	(50)	(50)	(49)	(50)
Carcinoma	2 (4%)			
Parathyroid Gland	(45)	(47)	(46)	(44)
Pituitary Gland	(49)	(50)	(48)	(50)
Pars Intermedia, Adenoma		1 (2%)		
Thyroid Gland	(50)	(50)	(49)	(50)
C-cell, Carcinoma	1 (2%)			
Follicular Cell, Carcinoma		1 (2%)		

## GENERAL BODY SYSTEM

None

## GENITAL SYSTEM

Coagulating Gland	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		22 (44%)	44 (90%)	48 (96%)
Ductus Deferens	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		23 (46%)	45 (92%)	33 (66%)
Epididymis	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Preputial Gland	(50)	(50)	(49)	(50)
Carcinoma				1 (2%)
Prostate	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		22 (44%)	45 (92%)	49 (98%)
Seminal Vesicle	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma,			1 (2%)	
Metastatic, Lung				
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra		22 (44%)	44 (90%)	48 (96%)
Testes	(50)	(50)	(49)	(50)
Interstitial Cell, Adenoma			1 (2%)	

## HEMATOPOIETIC SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Bone Marrow	(50)	(50)	(49)	(50)
Lymph Node	(2)	(1)	(2)	(0)
Bronchial, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (50%)	
Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (50%)	
Mediastinal, Carcinoma, Metastatic, Islets, Pancreatic	1 (50%)			
Lymph Node, Mandibular	(49)	(50)	(48)	(49)
Lymph Node, Mesenteric	(50)	(49)	(48)	(50)
Spleen	(50)	(50)	(49)	(49)
Hemangiosarcoma	2 (4%)			
Thymus	(41)	(42)	(40)	(49)
<b>INTEGUMENTARY SYSTEM</b>				
Skin	(50)	(50)	(49)	(50)
Subcutaneous Tissue, Fibrosarcoma	1 (2%)			
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)	1 (2%)		
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(49)	(50)
Skeletal Muscle	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Urethra		24 (48%)	45 (92%)	49 (98%)
Fibrosarcoma, Metastatic, Skin	1 (2%)			
<b>NERVOUS SYSTEM</b>				
Brain	(50)	(50)	(49)	(50)
Meningioma Malignant	1 (2%)			
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Adenoma	4 (8%)	12 (24%)	11 (22%)	5 (10%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)	4 (8%)	1 (2%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Alveolar/Bronchiolar Carcinoma	2 (4%)	1 (2%)	1 (2%)	
Alveolar/Bronchiolar Carcinoma, Multiple	1 (2%)		3 (6%)	
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Carcinoma, Metastatic, Urethra			1 (2%)	
Fibrosarcoma, Metastatic, Skin	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	5 (10%)	2 (4%)	2 (4%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach		1 (2%)		
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)	1 (2%)	1 (2%)	
Mediastinum, Fibrosarcoma, Metastatic, Skin	1 (2%)			
Nose	(50)	(50)	(49)	(50)
Pleura	(1)	(1)	(1)	(0)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (100%)	1 (100%)	
Fibrosarcoma, Metastatic, Skin	1 (100%)			
Trachea	(50)	(50)	(49)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Eye	(50)	(50)	(49)	(50)
Harderian Gland	(50)	(50)	(49)	(50)
Adenoma	6 (12%)	3 (6%)	1 (2%)	1 (2%)
<b>URINARY SYSTEM</b>				
Kidney	(50)	(50)	(49)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung			1 (2%)	
Carcinoma, Metastatic, Urethra				1 (2%)
Hemangiosarcoma	1 (2%)			
Ureter	(43)	(45)	(47)	(50)
Carcinoma, Metastatic, Urethra				6 (12%)
Transitional Epithelium, Carcinoma			1 (2%)	
Urethra	(48)	(50)	(49)	(50)
Glands, Transitional Epithelium, Carcinoma		32 (64%)	46 (94%)	49 (98%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Urinary Bladder Carcinoma, Metastatic, Urethra	(50)	(50) 1 (2%)	(49)	(50) 3 (6%)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(49)	*(50)
Histiocytic Sarcoma		1 (2%)		
Lymphoma Malignant	1 (2%)	1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
<b>Tumor Summary for Males</b>				
Total Animals with Primary Neoplasms (b)	41	45	46	49
Total Primary Neoplasms	74	101	93	63
Total Animals with Benign Neoplasms	30	32	24	10
Total Benign Neoplasms	38	49	31	10
Total Animals with Malignant Neoplasms	28	42	46	49
Total Malignant Neoplasms	36	52	62	53
Total Animals with Metastatic Neoplasms	9	27	45	49
Total Metastatic Neoplasms	24	121	238	240
Total Animals with Malignant Neoplasms Uncertain Primary Site				1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors



Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident	1		1	1
Moribund Sacrifice	6	9	9	21
Natural Death	8	11	8	8
Survivors				
Natural Death				1
Terminal Sacrifice	35	30	32	19
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(49)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Schwannoma Malignant, Metastatic, Skin			1 (2%)	
Gallbladder	(49)	(50)	(50)	(50)
Intestine Large, Cecum	(49)	(50)	(49)	(50)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Intestine Large, Colon	(49)	(50)	(49)	(50)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Intestine Large, Rectum	(49)	(50)	(50)	(50)
Intestine Small, Duodenum	(49)	(50)	(50)	(50)
Carcinoma				1 (2%)
Intestine Small, Jejunum	(49)	(50)	(50)	(50)
Carcinoma				1 (2%)
Leiomyosarcoma		1 (2%)		
Schwannoma Malignant, Metastatic, Skin				1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Liver	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin				2 (4%)
Fibrous Histiocytoma, Metastatic, Skin		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Hepatocellular Adenoma	3 (6%)	9 (18%)	2 (4%)	3 (6%)
Hepatocellular Adenoma, Multiple			1 (2%)	
Hepatocellular Carcinoma	2 (4%)	2 (4%)	1 (2%)	2 (4%)
Schwannoma Malignant, Metastatic, Skin		1 (2%)		1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Mesentery	(5)	(12)	(9)	(15)
Carcinoma, Metastatic, Islets, Pancreatic	1 (20%)			
Fibrosarcoma, Metastatic, Skin				2 (13%)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum		1 (8%)		
Schwannoma Malignant, Metastatic, Skin		1 (8%)		2 (13%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (7%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (11%)	
Pancreas	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin				2 (4%)
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Acinus, Adenoma		1 (2%)		
Salivary Glands	(49)	(50)	(50)	(50)
Squamous Cell Carcinoma			1 (2%)	
Stomach, Forestomach	(49)	(50)	(50)	(50)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma		1 (2%)	1 (2%)	4 (8%)
Squamous Cell Papilloma	2 (4%)	1 (2%)	1 (2%)	
Stomach, Glandular	(49)	(50)	(50)	(50)
Carcinoma				1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach				3 (6%)
Tongue	(0)	(1)	(0)	(1)
Squamous Cell Carcinoma				1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Tooth	(2)	(0)	(0)	(0)
<b>CARDIOVASCULAR SYSTEM</b>				
Blood Vessel	(49)	(50)	(50)	(50)
Heart	(49)	(50)	(50)	(50)
Schwannoma Malignant, Metastatic, Skin			1 (2%)	
<b>ENDOCRINE SYSTEM</b>				
Adrenal Cortex	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Islets, Pancreatic	1 (2%)			
Fibrosarcoma, Metastatic, Skin				1 (2%)
Leiomyosarcoma, Metastatic, Intestine		1 (2%)		
Small, Jejunum				
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Adrenal Medulla	(49)	(50)	(50)	(50)
Pheochromocytoma Malignant	1 (2%)			
Islets, Pancreatic	(49)	(50)	(50)	(50)
Adenoma	1 (2%)			
Carcinoma	1 (2%)			
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Parathyroid Gland	(43)	(47)	(48)	(41)
Pituitary Gland	(49)	(49)	(50)	(50)
Pars Distalis, Adenoma	1 (2%)	1 (2%)	3 (6%)	
Thyroid Gland	(49)	(50)	(50)	(50)
Bilateral, Follicular Cell, Carcinoma	1 (2%)			
C-cell, Adenoma			1 (2%)	
Follicular Cell, Adenoma		2 (4%)		
Follicular Cell, Carcinoma	1 (2%)			1 (2%)
<b>GENERAL BODY SYSTEM</b>				
None				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
<b>GENITAL SYSTEM</b>				
Clitoral Gland	(49)	(50)	(49)	(50)
Carcinoma	1 (2%)	1 (2%)		
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Ovary	(49)	(50)	(50)	(50)
Cystadenoma	2 (4%)			
Fibrosarcoma, Metastatic, Skin				1 (2%)
Hemangioma	1 (2%)			
Luteoma		1 (2%)		1 (2%)
Sarcoma Stromal, Metastatic, Uterus			1 (2%)	
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Teratoma Benign	1 (2%)			
Oviduct	(0)	(0)	(1)	(0)
Uterus	(49)	(50)	(50)	(50)
Carcinoma			1 (2%)	1 (2%)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Hemangiosarcoma		1 (2%)		
Sarcoma Stromal		2 (4%)	1 (2%)	
Cervix, Squamous Cell Carcinoma, Metastatic, Vagina			1 (2%)	
Vagina	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Uterus			1 (2%)	
Granular Cell Tumor Benign			1 (2%)	
Sarcoma Stromal, Metastatic, Uterus			1 (2%)	
Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Squamous Cell Carcinoma			1 (2%)	
<b>HEMATOPOIETIC SYSTEM</b>				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Lymph Node	(7)	(8)	(9)	(16)
Fibrosarcoma, Metastatic, Skin	1 (14%)			1 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (6%)
Inguinal, Fibrosarcoma, Metastatic, Skin				1 (6%)
Mediastinal, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (6%)
Mediastinal, Fibrosarcoma, Metastatic, Skin		1 (13%)	1 (11%)	2 (13%)
Mediastinal, Schwannoma Malignant, Metastatic, Skin		1 (13%)		
Mediastinal, Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (6%)
Pancreatic, Fibrosarcoma, Metastatic, Skin				1 (6%)
Pancreatic, Schwannoma Malignant, Metastatic, Skin		1 (13%)		
Lymph Node, Mandibular	(49)	(49)	(50)	(49)
Lymph Node, Mesenteric	(48)	(49)	(48)	(49)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Spleen	(49)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skin				2 (4%)
Hemangiosarcoma		1 (2%)		
Thymus	(48)	(48)	(45)	(48)
Fibrosarcoma, Metastatic, Skin				1 (2%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Thymoma Benign	1 (2%)			
<b>INTEGUMENTARY SYSTEM</b>				
Mammary Gland	(49)	(50)	(50)	(50)
Skin	(49)	(50)	(50)	(50)
Squamous Cell Papilloma	1 (2%)			
Subcutaneous Tissue, Fibroma			1 (2%)	
Subcutaneous Tissue, Fibrosarcoma	1 (2%)	6 (12%)	5 (10%)	7 (14%)
Subcutaneous Tissue, Fibrosarcoma, Multiple				1 (2%)
Subcutaneous Tissue, Fibrous Histiocytoma		1 (2%)		
Subcutaneous Tissue, Mast Cell Tumor				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Benign Subcutaneous Tissue, Mast Cell Tumor				1 (2%)
Malignant Subcutaneous Tissue, Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Subcutaneous Tissue, Schwannoma Malignant	1 (2%)	2 (4%)	2 (4%)	4 (8%)
<b>MUSCULOSKELETAL SYSTEM</b>				
Bone	(50)	(50)	(50)	(50)
Osteosarcoma		1 (2%)		
Skeletal Muscle	(4)	(5)	(1)	(8)
Fibrosarcoma, Metastatic, Skin		2 (40%)		3 (38%)
Leiomyosarcoma, Metastatic, Intestine Small, Jejunum		1 (20%)		
Rhabdomyosarcoma	2 (50%)			
Schwannoma Malignant, Metastatic, Skin	1 (25%)		1 (100%)	2 (25%)
Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (13%)
<b>NERVOUS SYSTEM</b>				
Brain	(49)	(50)	(50)	(50)
Peripheral Nerve	(0)	(2)	(1)	(0)
Spinal Cord	(0)	(1)	(1)	(0)
<b>RESPIRATORY SYSTEM</b>				
Lung	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	3 (6%)	6 (12%)	4 (8%)	6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple				1 (2%)
Alveolar/Bronchiolar Carcinoma		2 (4%)	1 (2%)	4 (8%)
Carcinoma, Metastatic, Clitoral Gland	1 (2%)			
Cystic Keratinizing Epithelioma				1 (2%)
Cystic Keratinizing Epithelioma, Multiple				1 (2%)
Fibrosarcoma, Metastatic, Skin		2 (4%)	1 (2%)	3 (6%)
Hepatocellular Carcinoma, Metastatic,	2 (4%)			1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
Liver				
Rhabdomyosarcoma, Metastatic, Skeletal Muscle	1 (2%)			
Schwannoma Malignant, Metastatic, Skin			1 (2%)	
Squamous Cell Carcinoma, Metastatic, Stomach, Forestomach			1 (2%)	
Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Mediastinum, Fibrosarcoma, Metastatic, Skin			1 (2%)	1 (2%)
Mediastinum, Schwannoma Malignant, Metastatic, Skin		1 (2%)		
Mediastinum, Schwannoma Malignant, Metastatic, Uncertain Primary Site				1 (2%)
Nose	(50)	(50)	(50)	(50)
<b>SPECIAL SENSES SYSTEM</b>				
Ear	(1)	(0)	(1)	(2)
Eye	(49)	(50)	(50)	(49)
Retina, Melanoma Benign				1 (2%)
Harderian Gland	(49)	(50)	(49)	(49)
Adenoma	14 (29%)	6 (12%)	9 (18%)	5 (10%)
<b>URINARY SYSTEM</b>				
Kidney	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Ureter				1 (2%)
Fibrosarcoma, Metastatic, Skin				2 (4%)
Ureter	(0)	(1)	(0)	(2)
Transitional Epithelium, Carcinoma				1 (50%)
Urethra	(49)	(50)	(49)	(49)
Glands, Transitional Epithelium, Carcinoma				2 (4%)
Urinary Bladder	(49)	(50)	(50)	(50)
Carcinoma, Metastatic, Urethra				1 (2%)
Carcinoma, Metastatic, Uterus			1 (2%)	
Fibrosarcoma, Metastatic, Skin				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	2 (4%)	1 (2%)	2 (4%)
Lymphoma Malignant	2 (4%)	5 (10%)	8 (16%)	7 (14%)
Mesothelioma Malignant			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

\* Number of animals with any tissue examined microscopically



Test Type: CHRONIC

3,3',4,4'-Tetrachloroazobenzene

Time Report Requested: 09:10:26

Route: GAVAGE

CAS Number: 14047-09-7

First Dose M/F: 02/04/03 / 02/03/03

Species/Strain: MICE/B6C3F1

Lab: BAT

---

B6C3F1 MICE FEMALE	0 MG/KG	3 MG/KG	10 MG/KG	30 MG/KG
--------------------	---------	---------	----------	----------

---

**Tumor Summary for Females**

<b>Total Animals with Primary Neoplasms (b)</b>	29	37	34	38
<b>Total Primary Neoplasms</b>	44	56	47	61
<b>Total Animals with Benign Neoplasms</b>	24	23	20	17
<b>Total Benign Neoplasms</b>	30	27	23	20
<b>Total Animals with Malignant Neoplasms</b>	13	23	21	33
<b>Total Malignant Neoplasms</b>	14	29	24	41
<b>Total Animals with Metastatic Neoplasms</b>	7	6	8	12
<b>Total Metastatic Neoplasms</b>	11	18	22	58
<b>Total Animals with Malignant Neoplasms Uncertain Primary Site</b>				1
<b>Total Animals with Neoplasms Uncertain-Benign or Malignant</b>				
<b>Total Uncertain Neoplasms</b>				

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors